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Abstract
It is widely assumed that genotoxin-induced damage (e.g., G-to-T transversions) to the tumor
suppressor gene, p53, is a direct cause of cancer. However, genotoxins also induce the stress
response, which upregulates p53 transcription and the formation of secondary structures from
ssDNA. Since unpaired bases are thermodynamically unstable and intrinsically mutable, increased
transcription could be the cause of hypermutation, and thus cancer. Support for this hypothesis has
been obtained by analyzing 6662 mutations in all types of cancer compared to lung and colon
cancers, using the p53 mutation database. The data suggest that genotoxins have two independent
effects: first, they induce p53 transcription, which increases the number of mutable bases that
determine the incidence of cancer. Second, genotoxins may alter the fate, or ultimate mutation of
a mutable base, for example, by causing more of the available mutable Gs to mutate to T, leaving
fewer to mutate to A. Such effects on the fate of mutable bases have no impact on the incidence
of cancer, as both types of mutations lead to cancer.

Background
Base damage to p53
The wild-type p53 protein inhibits neoplastic transformations as well as tumor growth. Moreover, if DNA damage
occurs, p53 is induced and maintains the integrity of the
genome by causing cell cycle arrest, to allow for repairs or,
in the event of severe damage, by sacrificing the damaged
cells (apoptosis). More than half of all cancers are associated with mutations in the p53 gene [1-3], and the vast
majority of these occur in the sequence-specific DNA
binding domain. DNA strand breakage and genetic instability are generally thought to arise as a result of direct
base damage by genotoxic stressors, such as reactive oxy-

gen species, which are not only in the environment but are
formed in vivo under normal physiological conditions. An
extensive literature documents the effect of genotoxins
directly on the p53 gene [4,5]. Of particular importance in
the present context are genotoxin-induced G:C-to-T:A
transversions that occur at high frequencies in some cancers [6-8]. While these transversions are relatively rare in
most mutable genes, they represent a "signature" p53
mutation in experiments which document DNA damage
by carcinogens. These studies appear to implicate base
damage as the direct cause of p53 mutations, and to suggest that such damage increases the incidence of lung cancer.
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However, severe base damage results in apoptosis in vivo,
and is unlikely to foster the creation of robust cancer cells.
A more conducive environment for the development of
cancer may emerge from a response to relatively mild
DNA damage that activates stress response mechanisms
[9] and upregulates p53 transcription. Transcription drives
secondary structures which expose unpaired bases for
hypermutation at specific sites ("hot spots"). Mutations in
p53 inactivate the protein, which regulates interactions
including the coordination of DNA repair with the rate of
cell growth. These relationships will be specifically disrupted without significant damage to metabolism in general, providing ideal conditions for the creation and
selection of cells with high rates of cell division, thus leading to tumorigenesis. This "directed" mutagenic mechanism, dependent upon the stress response rather than
random base damage, is more likely to be responsible for
the evolution of hypermutable bases in critical regulatory
genes such as p53.
The stress response
A number of investigations in the microbial world have
provided evidence that environmental stressors derepress
and/or activate transcription specifically in genes that
must mutate to overcome the stress [10,11]. The implications of this mutagenic mechanism for evolution are profound [12,13]. The increased rate of stress-induced
transcription based on mRNA accumulation and half-life
has been correlated with mutation rates, and predicted
effects of promoter strength and supercoiling on mutation
frequencies have been demonstrated in prokaryotes
[10,14,15]. In higher organisms, only a few studies supporting this mechanism are available [16,17]; also, convincing evidence exists for a direct dependence of
mutation frequency on the rate of transcription during
somatic hypermutation in the immune response [18].

Genotoxic stressors cause strong promoter activation and
upregulation of p53 transcription, which could increase
p53 mutation frequencies. The persistent over-expression
of p53 protein is commonly associated with the accumulation of p53 mutations and tumorigenesis [19,20]. The
cellular stress response involves a large number of genes
in a complex network, and genotoxins induce transcriptional upregulation of p53 by both indirect and direct
means. DNA-damaging genotoxins elicit a strong p53 protein-dependent response resulting in upregulation of p53
transcription [9]. This activation of transcription occurs
either by direct interaction with the basal p53 promoter
[21] or by indirect upregulation, which typically involves
activation by the ubiquitous transcription factor, NF-κB.
Specifically, benzo [a]pyrene, a potent genotoxic component of cigarette smoke, upregulates p53 transcription via
induction of NF-κB [22]. As the p53 gene is responsive to
many stress-related signals [23,24], its expression is upreg-
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ulated by a variety of genotoxic stressors. The activation of
p53 transcription will drive supercoiling, which creates
and stabilizes ssDNA secondary structures containing
unpaired bases that are intrinsically mutable [25,26].
Therefore transcription, per se, could promote hypermutation and ultimately, cancer.
Intrinsically mutable bases
Unpaired bases of ssDNA are thermodynamically unstable, and point mutations occur by known chemical mechanisms having finite, significant activation energies under
physiological conditions. For example, the hydrolytic
deamination of cytosine in ssDNA occurs 160 times more
frequently than in dsDNA, and CpG sequences are methylated non-enzymatically by S-adenosylmethionine, rendering them 40 times more susceptible to deamination
than non-methylated sequences [26]. In the p53 gene,
most of the hypermutable bases are methylated CpGs.
Two major non-enzymatic mutagenic events, the hydrolytic deamination of cytosine and the oxidation of guanine, are estimated to occur 100–500 times per day in
each human cell, and 2000–10000 purine bases turn over
per day in each cell due to hydrolytic depurination and
repair. Thus, G and C are much more mutable by these
mechanisms than A and T, and, because of its size, A is
more likely than C or T to replace G at apurinic sites
[26,27]. In human genetic disease, 35% of single base
mutations are in CpG dinucleotides and over 90% are Cto-T or G-to-A mutations occurring at a frequency 42-fold
higher than that predicted by chance [28]. Thus, these are
the primary "default" or background mutations in ssDNA
that are determined by the inherent chemical instability of
each base and the extent to which it is exposed during
events such as replication and transcription.

Transcription-induced intrinsic mutagenesis, due only to
the extent to which a base is unpaired in ssDNA, correlates
with mutation frequencies in p53 [17]. Interestingly, this
circumstance would be difficult to distinguish from one
that is also dependent upon, and therefore superimposed
upon base exposure; for example, genotoxin-induced Gto-T transversions, and enzyme-catalyzed mutations, both
of which are more effective on ssDNA than dsDNA.
Predicting base mutability in vivo
In previous studies a computer algorithm (mfg) has been
used to simulate the formation of secondary structures in
ssDNA during transcription and predict the relative mutability of unpaired bases in these structures [11]. This program performs a sliding window analysis of any given
sequence, in which a chosen length of nucleotides is
folded successively, beginning with each base in the
sequence. Mfg interfaces with another computer program
(mfold) that reports all possible secondary structures that
can form from each folded segment, in order of their sta-
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bility. The mfg program predicts (i.e., calculates) the mutability of each unpaired base from two key variables: a) the
stability of the most stable secondary structure in which
the base is unpaired, and b) the percent of total folds in
which it is unpaired. The Mutability Index (MI) is the
product of these two factors: the stability (-ΔG) of the
most stable SLS multiplied by percent unpaired.

mechanism for inducing the level of transcription in p53
that leads to mutagenesis.
As the implications of the previous analyses are not yet
widely recognized, an original analysis of the p53 mutation database is presented here. These data provide strong
support regarding the roles of genotoxins, base damage,
and transcription with respect to the incidence of cancer.
Thus, new lines of evidence support the conclusion that
genotoxins: (1) activate p53 transcription and hypermutation, which increases the number of mutable bases and
thus the incidence of cancer, and (2) alter the fate of mutable bases, which does not affect the incidence of cancer.

The computer algorithm, mfg, has been used to analyze
hypermutable codons in p53 [17]. Using the non-transcribed strand, twelve hypermutable bases (the first two
positions of codons 175, 245, 248, 249, 273, and 282)
were analyzed (a total of 3492 mutations), and the computer-predicted MIs were found to correlate (r2 = 0.77; p =
0.0002) with the mutation frequencies. No correlation
was found using the transcribed strand (r2 = 0.27; p = 0.1).
To determine the relative contribution of percent
unpaired and -ΔG to MI, all three are plotted independently against mutation frequency (Fig. 1). Secondary
structure stability shows no correlation with mutation frequency (Fig. 1c) while the correlation with percent
unpaired (Fig. 1b) is comparable to that of MI (Fig. 1a).
Therefore, the extent to which a base is unpaired during
transcription is a much better predictor of base mutability
(in p53) than the stability of the most stable structure in
which it is unpaired. Another variable that can be analyzed by this program is the effect of transcription level,
which correlates with the amount of RNA transcript and
ssDNA formed [29,30]. Over a broad range of transcription levels (> 40 nt window size) predicted mutation frequencies increase incrementally, suggesting a threshold

MI
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r2 = 0.77
p = 0.0002

A systems analysis of 6662 mutations in the International
Agency for Research on Cancer TP53 Mutation Database
(version R4) [31,32] has revealed relationships and mechanisms not easily examined in the laboratory. Due to the
rarity of mutations, a large database is essential for obtaining reliable values in assessing the origin and fate of mutable bases in cancers. Moreover, these mutations occurred
under physiological conditions, whereas experimental
conditions for analyzing effects of genotoxins in vitro may
not reflect conditions in vivo. In our analyses, the dual role
of genotoxins was discovered only in light of two kinds of
information extracted from the same large p53 mutation
database: first, genotoxins induce a stress response that
upregulates p53 transcription and mutation frequency to
a comparable extent in lung cancer as in all types of cancer; this frequency determines the incidence of cancer.
Second, base damage by genotoxins increase the G-to-T
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the y-axis are obtained from the mfg computer program that simulates transcription [17].
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Table 1: Mutations in lung compared to all cancers (including lung) in p53 codons 210–290

Total number of all
mutations in 240 nt (6662)
Percent of total
Number of lung mutations
in 240 nt (875)
Percent of lung
Difference in total
mutations compared to
lung mutations

A

C

G

T

865

1875

3375

547

13.0%

28.1%

50.7%

8.2%

126

198

484

67

14.4%

22.6%

55.3%

7.7%

+1.4%

-5.5%

+4.6%

-0.5%

All point mutations in codons 210–290 were analyzed.
Table 1 shows the total number of all mutations (including lung) compared to lung mutations and the propensity of each of the four bases to
mutate to any other base. This sequence is composed of 56 As, 66 Cs, 67 Gs, and 54 Ts. Mutations of G are shown in bold.
Table 2: Mutations of G to other bases in p53 codons 210–290

A

C

T

Total G mutations including lung
(3375)
Percent of total

2082

351

942

61.7%

10.4%

27.9%

Lung G mutations (484)
Percent of lung

153
31.6%

74
15.3%

257
53.1%

Difference in total G
mutations due to the
presence of lung G mutations

-30.1%

+4.9%

+25.2%

All point mutations in codons 210–290 were analyzed.
Table 2 shows the ultimate fate of G mutations in all cancers due to lung cancers, with G-to-A and G-to-T mutations in bold.

Table 3: Mutations of C to other bases in p53 codons 210–290

A

G

T

Total C mutations including lung
(1875)
Percent of total

157

187

1531

8.4%

10.0%

81.6%

Lung C mutations (198)
Percent of lung

21
10.6%

31
15.7%

146
73.7%

Difference in total C mutations
due to the presence of lung C
mutations

+2.2%

+5.7%

-7.9%

All point mutations in codons 210–290 were analyzed.
In Table 3, the ultimate fate of C mutations in all cancers due to the presence of lung cancers is shown.

versus the G-to-A ratio in lung cancer; however, this has
no effect on the incidence of cancer. This key distinction
is essential to understanding the mechanisms involved.
Table 1 summarizes the relative number of mutations in
the four bases and Tables 2 and 3 show the fates of G and

C mutations in codons 210–290 of p53 for all types of
cancers (6662 total mutations, including lung), compared
to lung cancer mutations exclusively (875). The relative
percent of mutations in the four bases is remarkably similar in lung and in all cancers, especially in view of the presumed effect of genotoxins on mutations in lung tissue
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(Table 1). The most striking observation is that, although
the percent of G mutations in lung cancers is comparable
to the percent in all types of cancers (55.3% versus
50.7%), the base to which G most frequently mutates is
clearly different in the two data sets (Table 2). Of the total
G mutations in all cancers (including lung), 61.7% are to
A and 27.9% are to T, whereas in lung cancer mutations,
31.6% of G mutations are to A and 53.1% are to T. Thus,
the ultimate fate of mutable G bases in lung cancers
appears to be strongly influenced by the unusually potent
genotoxic agents in smoke. The observation that G-to-A
default mutations decrease to approximately the same
extent as G-to-T mutations increase suggests that these
mutations share ("compete" for) the same source of available background mutable Gs. If lung cancers were
excluded from "all cancers", it would not be possible to
depict the competition in all cancers between (defaultinduced) G-to-A mutations and (genotoxin-induced) Gto-T mutations for the (limited number of transcriptioninduced) available mutable Gs. The relative percent of
mutations in the four bases is similar in lung and in all
mutations, suggesting a common regulatory mechanism
that is different from that which determines the fate of G
mutations. Note that a distinction is made between base
mutability, or the propensity of a base to mutate (deter-

a

mined by transcription), and the ultimate fate, or final
mutation that occurs (dependent upon the absence or
presence of a mutagen). It is the number of mutable bases
that correlate with the incidence of cancer. Having distinguished between the propensity of a base to mutate and
the fate or final outcome of a mutation, it should be noted
that lung mutations are characterized by a minor increase
in the number of mutable Gs (4.6%) and As (1.4%),
which could be critical to the incidence of this type of cancer.
Figure 2a is a visual description of the fate of G mutations
in all cancers (including lung) compared to lung cancers
(Tables 1, 2, 3), and Figure 2b depicts the "mutation flow"
or relative frequencies with which mutations of G are generated during transcription and mutate to the other three
bases, all of which result in cancer. The proposed dual
effects of genotoxins on transcription and on base damage
are also noted.
When mutations of C were analyzed (Table 3), relatively
small differences were seen in the fate of total mutable Cs
due to lung cancer C mutations. While C-to-T mutations
predominate in the data sets of both lung and all types of

b
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Cancer
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Figure
Visual depictions
2
of the frequencies and fates of G mutations due to lung cancers in p53
Visual depictions of the frequencies and fates of G mutations due to lung cancers in p53. (a) In lung cancer mutations compared to all cancers, there is a decrease of 30.1% (orange) in G-to-A mutations, an increase of 25.2% (green) in G-to-T mutations, and an increase of 4.9% (blue) in G-to-C mutations. (b) The relative number or frequency of G mutations (gray),
resulting from transcription, compared to the relative frequencies with which these Gs mutate to the other three bases, following the same color scheme as in (a). The number of cancers is equal to the number of mutable Gs. The thickness of each
arrow is proportional to percent mutation frequencies, and the dual role of genotoxins is indicated. The data are derived from
Tables 1-3.
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Table 4: Mutations in colon compared to all cancers (including colon) in p53 codons 210–290

Total number of all
mutations in 240 nt (6662)
Percent of total
Number of colon
mutations in 240 nt (651)
Percent of colon
Difference in total
mutations compared to
colon mutations

A

C

G

T

865

1875

3375

547

13.0%

28.1%

50.7%

8.2%

42

260

317

32

6.4%

40.0%

48.7%

4.9%

-6.6%

+11.9%

-2.0%

-3.3%

Analyzed as in Tables 1-3 for colon cancer.
Table 4 shows the total number of all mutations (including colon) compared to colon mutations and the propensity of each of the four bases to
mutate to any other base (with mutations of both G and C in bold).

Table 5: Mutations of G to other bases in p53 codons 210–290

A

C

T

Total G mutations including colon
(3375)
Percent of total

2082

351

942

61.7%

10.4%

27.9%

Colon G mutations (317)
Percent of colon

257
81.1%

19
6.0%

41
12.9%

Difference in total G
mutations due to the
presence of colon G
mutations

+19.4%

-4.4%

-15.0%

A

G

T

Analyzed as in Tables 1-3 for colon cancer.
Table 5 shows the ultimate fate of G mutations in all cancers due to colon cancers.

Table 6: Mutations of C to other bases in p53 codons 210–290

Total C mutations including colon
(1875)
Percent of total

157

187

1531

8.4%

10.0%

81.6%

Colon C mutations (260)
Percent of colon

8
3.1%

10
3.8%

242
93.1%

Difference in total C
mutations due to the
presence of colon C mutations

-5.3%

-6.2%

+11.5%

Analyzed as in Tables 1-3 for colon cancer.
Table 6 shows the ultimate fate of C mutations in all types of cancers due to the presence of colon cancers.

cancers, proportionally fewer (7.9%) occur in the former
case.
A similar analysis (Tables 4, 5, 6) compares p53 mutations
in all cancers to colon cancers. In contrast to lung muta-

tions, in which G-to-T mutations predominate, the most
frequent G mutation in colon cancer is G-to-A. Also, while
the relative number of G mutations increase to a minor
extent in lung (4.6%), they decrease in colon cancer
(2.0%). However, a significant increase (11.9%) occurs in
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the relative number of mutable Cs, suggesting an association with the development of colon cancer. Moreover, the
fate of mutable Gs and Cs is in striking contrast to that
seen in lung cancer mutations. The fate of mutable Cs is
primarily to Ts, while there are relatively more G-to-A
default mutations compared to G-to-T mutations. However, as all of these mutation fates are associated with cancer, they do not alter the frequency with which it occurs.
The increased availability of background mutable Cs may
be critical to the increased frequency of colon cancer.
These results also suggest that a different mutagenic mechanism is operative in colon versus lung cancer.
Results from the analyses of lung cancer mutations in p53
codons 210–290 (Tables 1, 2, 3) prompted a similar
examination of 15 hypermutable bases in codons 213,
220, 245, 248, 249, 273, and 282 (the first two positions
of all codons plus the third position of codon 249)
(Tables 7, 8, 9). Note that the evolution of hypermutable
bases has resulted in twice as many mutable G sites as C
sites in this more selective hypermutable subset, and that
there is a clear increase (10.7%) in the number of G mutations, again suggesting a causal relationship with the incidence of lung cancer. As in Table 2, compensatory shifts
are seen in the percent of Gs that mutate to A versus T in
lung cancer mutations compared to total mutations
(Table 8). The data show a 34.5% increase in G-to-T and
a 6.6% increase in G-to-C mutations in lung cancers,
accompanied by a 41.1% decrease in G mutations to A.
This is consistent with a shared source of mutable Gs, as
seen in Table 2. Partitioning the fates of mutable Cs to the
other bases also occurs (Table 9), but the effects are
minor.
In p53, an excellent correlation is seen between observed
and predicted mutation frequency for the non-transcribed
strand (Fig. 1), while no correlation exists for the transcribed strand. Thus, while a C-to-A transversion on the
transcribed strand could occur to produce a T in the nontranscribed strand via mismatch repair, this mechanism
probably makes a small contribution to the results of our
analyses.
Codons 248 and 273 play a critical role in DNA binding,
in addition to having the highest predicted and observed
mutation frequencies in the p53 mutation database [17].
These codons were therefore chosen to further refine our
analyses of the hypermutable bases. The results are seen in
Tables 10, 11, 12, and a comparison with Tables 7, 8, 9
indicates that the characteristics of these two codons are
typical of those seen for the other hypermutable lung cancer analyses.

http://www.cancerci.com/content/6/1/27

Conclusion
These studies indicate that genotoxin-induced G-to-T base
damage to p53 is not correlated with the incidence of lung
cancer, which must therefore be due to a different mechanism. We propose that mild base damage by genotoxins
provokes the stress response during which p53 promoter
elements are activated, leading to transcription, hypermutation, the loss of p53 regulatory functions, and ultimately
to cancer. A variety of experimental evidence supports this
mechanism: (a) genotoxins induce upregulation of p53
transcription [9,21-24]; (b) persistently upregulated p53
expression is associated with the accumulation of p53
mutations and tumorigenesis [19,20]; (c) intrinsically
mutable unpaired bases in secondary structures are
formed during transcription [26,29,30]; and (d) an excellent correlation exists (Fig. 1) between observed mutation
frequencies in p53 and base mutability predicted by a
model of transcription-induced mutagenesis [17].
Although these experimental lines of evidence do not
address the possibility of a dual role for carcinogens in
mutagenesis, the insights obtained from Tables 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12 provide strong support for the existence of two different, as well as independent mechanisms
induced by genotoxins. The newly discovered relationships described above suggest that the same mechanism
regulates the number of mutable bases in lung cancer as
in all cancers, and that this mechanism (transcription) differs from that regulating the fate of the mutable bases, e.g.,
the number of available mutable Gs that mutate to T versus the number that mutate to A. Further, the data
describe the two independent roles of genotoxins: first,
they upregulate p53 transcription and increase the availability of mutable bases, which determines the incidence of
cancer, and second, they inflict base damage, e.g., increase
the ratio of G-to-T versus G-to-A mutations, which has no
affect on the frequency of cancer. These analyses are consistent with the conclusion that transcription-exposed
mutable bases determine the incidence of cancer, which is
also the conclusion of an independent analysis of hypermutable bases using the computer algorithm, mfg (Fig. 1).
The development of cancer clearly involves a complex
series of mutagenic and selective events. It now appears
that these events may include the participation of transcription-driven secondary structures and intrinsically
mutable bases encoded within the p53 gene.
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Table 7: Mutations in lung compared to all cancers in fifteen hypermutable bases of p53

Total number of all
mutations in 15 nt (3292)
Percent of total
Number of lung mutations
in 15 nt (407)
Percent of lung
Difference in total
mutations compared to
lung mutations

A

C

G

T

225

1195

1857

15

6.8%

36.3%

56.4%

0.5%

26

107

273

1

6.4%

26.3%

67.1%

0.2%

-0.4%

-10.0%

+10.7%

-0.3%

These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249.
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 7 shows the total number of all mutations (including lung) compared to
lung mutations and the propensity of these mutable bases to mutate to any other base (with mutations of G in bold).

Table 8: Mutations of G to other bases in fifteen hypermutable bases of p53

A

C

T

Total G mutations including lung
(1857)
Percent of total

1214

107

536

65.3%

5.8%

28.9%

Lung G mutations (273)
Percent of lung

66
24.2%

34
12.4%

173
63.4%

Difference in total G
mutations due to the
presence of lung G mutations

-41.1%

+6.6%

+34.5%

These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249.
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 8 shows the ultimate fate of G mutations in all cancers due to lung
mutations (with G-to-A and G-to-T in bold).
Table 9: Mutations of C to other bases in fifteen hypermutable bases of p53

A

G

T

Total C mutations including lung
(1195)
Percent of total

17

49

1129

1.4%

4.1%

94.5%

Lung C mutations (107)
Percent of lung

3
2.8%

9
8.4%

95
88.8%

Difference in total C mutations
due to the presence of lung C
mutations

+1.4%

+4.3%

-5.7%

These hypermutable bases consist of the first two positions of codons 213, 220, 245, 248, 273, and 282 and all positions in codon 249.
The composition of the bases analyzed is 2 As, 4 Cs, 8Gs, and 1T. Table 9 shows the ultimate fate of C mutations in all cancers due to the
presence of lung cancers.
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Table 10: Mutations in lung compared to all cancers in hypermutable codons 248 and 273

A

C

G

T

Total number of mutations
in 4 nt (1775)
Percent of total

0

728

1047

0

0

41.0%

59.0%

0

Number of lung mutations
in 4 nt (187)
Percent of lung

0

63

124

0

0

33.7%

66.3%

0

0

-7.3%

+7.3%

0

Difference in total
mutations compared to
lung mutations

These hypermutable bases consist of the first two positions of codons 248 and 273.
The composition of the bases analyzed is 2 Cs and 2Gs. Table 10 shows the total number of mutations (including lung) compared to lung
mutations and the propensity of these mutable bases to mutate to any other base (with total mutations of G in bold).

Table 11: Mutations of G to other bases in hypermutable codons 248 and 273

A

C

T

Total G mutations including lung
(1047)
Percent of total

863

31

153

82.4%

3.0%

14.6%

Lung G mutations (124)
Percent of lung

46
37.1%

9
7.3%

69
55.6%

Difference in total G
mutations due to the
presence of lung mutations

-45.3%

+4.3%

+41.0%

These hypermutable bases consist of the first two positions of codons 248 and 273.
The composition of the bases analyzed is 2 Cs and 2Gs. Table 11 shows the ultimate fate of G mutations in all cancers due to lung mutations (with
G-to-A and G-to-T in bold).
Table 12: Mutations of C to other bases in hypermutable codons 248 and 273

A

G

T

Total C mutations including lung
(728)
Percent of total

11

21

696

1.5%

2.9%

95.6%

Lung mutations (63)
Percent of lung

3
4.8%

2
3.2%

58
92.1%

Difference in total C mutations
due to the presence of lung C
mutations

+3.3%

+0.3%

-3.5%

These hypermutable bases consist of the first two positions of codons 248 and 273.
The composition of the bases analyzed is 2 Cs and 2Gs. Table 12 shows the ultimate fate of C mutations in all cancers due to the presence of lung
cancers.
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